Floatz logo

ANTI-CD20/CD3 MONOCLONAL ANTIBODY REGN1979

Diffuse Large B-Cell Lymphoma

University of Washingtonmonoclonal_antibodyPhase 3Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
81/ 100

Competitive context

252 Active assets in the Diffuse Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Vincristine sulfate
National Cancer Institute (NCI)
Phase 2/3A
MELPHALAN
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
Nivestim
Ruijin Hospital
Phase 3BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 3BBB

View all 50 →

Same molecule, other indications

ANTI-CD20/CD3 MONOCLONAL ANTIBODY REGN1979 is also rated in:

B-cell non-Hodgkin lymphomaActive
BBB
Indicative · Phase 3
75 / 100
View asset →
follicular lymphomaActive
B
Indicative · Phase 3
62 / 100
View asset →
high grade B-cell lymphomaActive
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →